DOCSLIB.ORG

REVIEW of TUBERCULOSIS PREVENTION, CONTROL and CARE in AZERBAIJAN Office for Europe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
REVIEW of TUBERCULOSIS PREVENTION, CONTROL and CARE in AZERBAIJAN Office for Europe The WHO Regional REVIEW OF TUBERCULOSIS PREVENTION, CONTROL AND CARE IN AZERBAIJAN Office for Europe The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves. Member States Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Review of Iceland Ireland Israel Italy Tuberculosis Kazakhstan Edited by: Masoud Dara Kyrgyzstan Latvia Ogtay Gozalov Lithuania Orkhan Javadli Prevention, Control Luxembourg Malta Nonna Turusbekova Monaco Montenegro and Care in Netherlands Norway Poland Portugal Azerbaijan Republic of Moldova Romania Russian Federation San Marino 11-17 April 2012 Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan The former Yugoslav Republic of Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan World Health Organization Regional Office for Europe UN City, Marmorvej 51, DK-2100 Copenhagen Ø, Denmark Tel.: +45 45 33 70 00 Fax: +45 33 70 01 Email: [email protected] Website: www.euro.who.int Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe UN City, Marmorvej 51 DK-2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office web site (http://www.euro.who.int/pubrequest). © World Health Organization 2013 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization. Written by Masoud Dara Ogtay Gozalov Kai Blondal Javahir Suleymanova Nestani Tukvadze Nonna Turusbekova Irina Eramova Alain Disu Ucha Nanava Susan Adolph Ekaterina Kurbatova Veriko Mirtskhulava Orkhan Javadli Sevim Ahmedov Bhavna Patel Samantha Huffman Edited by Masoud Dara Ogtay Gozalov Orkhan Javadli Nonna Turusbekova 2 TABLE of CONTENT ACRONYMS ........................................................................................................ 5 FULL LIST OF RECOMMENDATIONS: ............................................................. 10 BACKGROUND INFORMATION ........................................................................ 15 1.STRUCTURE OF TB PREVENTION, CONTROL AND CARE .............................19 2.SERVICE DELIVERY ....................................................................................... 21 3.HEALTH WORKFORCE ................................................................................. 47 4.INFORMATION ............................................................................................... 51 5.MEDICAL PRODUCTS, VACCINES, TECHNOLOGIES .................................... 56 6.FINANCING ................................................................................................... 62 7.LEADERSHIP AND GOVERNANCE ................................................................ 66 ANNEX I. TB-IC FACILITY RISK ASSESSMENT ................................................... 74 Annex II. Activity of Reference National Laboratory of Baku ........................ 82 Annex III. Contamination rates on BACTEC MGIT and Lowenstein-Jensen .. 83 Annex IV. List of the 1st line (non-GDF), the 2nd line anti-TB drugs, BCG, and Tuberculin currently used in the TB network of the Republic of Azerbaijan . 84 Annex V. Customs clearance of the 1st line anti-T drugs procured by ISC...... 85 Annex VI. Distribution of the 1st line anti-TB drugs ....................................... 86 Annex VII. CSOs participating in TB control program in Azerbaijan ............. 87 Annex VIII. List of National Counterparts Participating in Review ................91 Annex IX. Programme of the visit ................................................................. 93 Annex X. List of Mission Members ................................................................ 98 Annex XI. Field Visits .................................................................................. 100 Annex XII. References ................................................................................. 118 3 ACKNOWLEDGEMENTS The Ministry of Health shall be commended for their renewed commitment to TB and M/XDR-TB prevention and control. The authors of the report acknowledge the director of National TB Control programme, the director and staff of the National Institute of Tuberculosis, chief doctors, chief TB doctors and health care staff in the districts visited. Extensive review to TB prevention, Control and Care could only be conducted thanks to their full collaboration. Special gratitude goes to the Ministry of Justice for their transparency and collaboration. WHO Regional Office in Europe would like to thank national and international partners particularly the Global Fund to Fight AIDS, Tuberculosis and Malaria. 4 ACRONYMS ACSM Advocacy, Communication and Social Mobilization AEC Analytic Expertise Center AFB Acid-fast bacillus AR The Republic of Azerbaijan ART Antiretroviral therapy BCG bacille Calmette-Guérin (Antituberculosis Vaccine) BSC Biosafety Cabinet CAT Category CCM Country Coordinating Mechanism CM Capreomycin CMS Central Medical Store CS Cycloserine CSO Civil Society Organization CU Coordination Unit CXR Chest X-ray DOT Directly Observed Treatment DR Drug resistance DR-TB Drug-Resistant Tuberculosis DST Drug-Susceptibility Testing EIDSS Electronic Integrated Disease Surveillance System EMEA European Medicines Agency FELTP Field Epidemiology and Laboratory Training Program FDC Fixed-Dose Combination FLD First-line drugs FSU Former Soviet Union FWA Federal Way Assurance GDF Global Drug Facility GDP Good Distribution Practices GF The Global Fund to Fight AIDS, Tuberculosis and Malaria GIZ/GTZ German Agency for International Cooperation GLC The Green Light Committee GMP Good Manufacturing Practice HEC Hygiene – Epidemiological Centers HRD Human Resource Development IC Infection Control ICRC International Committee of the Red Cross IDPs Internally Displaced People IDU Injecting drug user INH Isoniazid INN International Non-proprietary Names IPT Insulin potentiation therapy IRB Institutional Review Board ISC Innovation and Supply Center ISO International Organization on Standardization KfW Reconstruction Credit Institute of Germany KM Kanamycin LFX Levofloxacin LTBI Latent Tuberculosis Infection LPA Line-probe assay M&E Monitoring and evaluation MDR-TB Multi-Drug-Resistant Tuberculosis MFX Moxifloxacin MGIT Mycobacteria growth indicator tube 5 MoH Ministry of Health MoJ Ministry of Justice MRA Medicines Regulatory Authority MTB Mycobacterium tuberculosis MTCT Mother-to-child transmission NAP National Action Plan NGO Non-Governmental Organization NTP National Tuberculosis Programme NRL National Reference Laboratories OFX Ofloxacin OOP Out-of pocket payments OPD Outpatient Department OR Operational Research PAS Para-aminosalicylic acid PDR Poly-Drug Resistant Tuberculosis PHC Primary Care Health Facility PHRC Public Health and Reforms Center PIU Project Implementation Unit PLWHA People living with HIV/AIDS PPD Purified protein derivative PTO Prothionamide PU Progress Update QA Quality Assurance QI Quality Improvement RAD Return after default R&R Recording and reporting RIF Resistance to rifampicin RMP Rifampin SAT Self-Administrated Treatment SES Socioeconomic Status SES Sanitary Epidemiological Station SLD Second-Line Drugs SRILD Scientific-Research Institute of Lung Diseases of AR SRL Supranational Reference Laboratory SSES State Sanitary and Epidemiological Surveillance STI Sexually Transmitted Infection STID Specialized Treatment Institution for Detainees TB Tuberculosis TST Tuberculin Skin Testing USAID United States Agency for International Development UV Ultraviolet WB World Bank WHO World Health Organization XDR-TB Extensively Drug-Resistant Tuberculosis Z Pyrazinamide 6 EXECUTIVE
Load more

Recommended publications
  • Conference of the Parties to the United Nations Convention Against
    United Nations CTOC/COP/WG.4/2015/INF/1/Rev.1 Conference of the Parties to the Distr.: General 26 November 2015 United Nations Convention against Transnational English/French/Spanish Organized Crime Working Group on Trafficking in Persons Vienna, 16-18 November 2015 LIST OF PARTICIPANTS States Parties Afghanistan Ayoob M. ERFANI, Ambassador, Permanent Representative, Permanent Mission to the United Nations, Vienna Hassan SOROOSH, Counsellor, Permanent Mission to the United Nations, Vienna Waheed AMIN, Second Secretary, Permanent Mission to the United Nations, Vienna Algeria Mohamed BENHOCINE, Ambassadeur, Représentant Permanent, Mission permanente auprès des Nations Unies, Vienne Billel HASSANI, Attaché, Mission permanente auprès des Nations Unies, Vienne Angola Maria DE JESUS FERREIRA, Ambassador, Permanent Representative, Permanent Mission to the United Nations, Vienna Mariano JOAO BAPTISTA, Minister Counsellor, Permanent Mission to the United Nations, Vienna Teresa Manuel BENTO DA SILVA, First Secretary, Permanent Mission to the United Nations, Vienna Paulo Nicolau CANDEIA, Second Secretary, Permanent Mission to the United Nations, Vienna Argentina Jorge Mariano JORDAN, Consejero, Representante Permanente Alterno, Misión Permanente ante las Naciones Unidas, Viena Armenia Areg HOVHANNISIAN, Deputy Permanent Representative, Permanent Mission to the United Nations, Vienna Lusine HAKOBYAN, Second Secretary, Human Rights and Humanitarian Issues Division Lena TERZIKYAN, Alternate Permanent Representative, Second Secretary, Permanent Mission
    [Show full text]
  • Review of the Global Fund's Business Model
    36th Board Meeting Review of the Global Fund Business Model GF/B36/28 16-17 November 2016, Montreux, Switzerland Board Discussion Purpose of the paper: This paper presents the findings from a study of the Global Fund business model. It outlines how the current business model operates, the benefits and challenges with the current model and potential options to strengthen the current model. It then presents possible options for the evolution of the business model for review and discussion by the Board. TABLE OF CONTENTS 1. DECISION POINT .................................................................................................................................... 3 2. RELEVANT PAST DECISIONS ................................................................................................................... 3 3. ACTION REQUIRED ................................................................................................................................. 3 4. EXECUTIVE SUMMARY ........................................................................................................................... 4 5. BACKGROUND ....................................................................................................................................... 8 5.1. EVOLUTION OF THE GLOBAL FUND’S BUSINESS MODEL .......................................................................................... 8 5.2. OVERVIEW OF THE CURRENT BUSINESS MODEL ...................................................................................................
    [Show full text]
  • 12 Th WHO National TB Programme Managers' Meeting and 16 Th
    12th WHO National TB Programme Managers’ Meeting and 16th Wolfheze Workshops The Hague, Netherlands 29-31 May 2013 MEETING REPORT Content Acronyms and abbreviations ...................................................................................... 3 Acknowledgements .................................................................................................... 3 Executive summary .................................................................................................... 4 Background ................................................................................................................ 5 Scope and purpose ..................................................................................................... 5 Opening Session ......................................................................................................... 7 Session 1: Follow-up of Berlin Declaration 2007, the Consolidated Action Plan to Prevent and Combat M/XDR-TB in WHO European Region 2011-2015 and the Framework Action Plan to Fight TB in the EU .............................................................. 9 Session 2: Intensified TB case-finding: yield and impact on TB epidemiology ............. 18 Session 3: Role of civil society in TB control .............................................................. 21 Session 4: Extrapulmonary TB - Situation analysis & challenges................................. 24 Session 5: TB in vulnerable populations (migrants & prisoners) ................................. 27 Session 6: Childhood TB ...........................................................................................
    [Show full text]
  • Data Collection Survey on Infrastructure Development in Central Asia and the Caucasus
    Azerbaijan Republic Data Collection Survey on Infrastructure Development in Central Asia and the Caucasus Final Report Azerbaijan MAY 2019 JAPAN INTERNATIONAL COOPERATION AGENCY (JICA) NOMURA RESEARCH INSTITUTE, LTD. 3R JR 19-006 Azerbaijan Republic Data Collection Survey on Infrastructure Development in Central Asia and the Caucasus Final Report Azerbaijan MAY 2019 JAPAN INTERNATIONAL COOPERATION AGENCY (JICA) NOMURA RESEARCH INSTITUTE, LTD. Table and Figures ....................................................................................................................................................... v List of Tables .......................................................................................................................................................... v List of Figures ...................................................................................................................................................... vii Abbreviations ............................................................................................................................................................. ix 1. Introduction ................................................................................................................................................... 1 1.1. Background ......................................................................................................................................... 1 1.2. Purpose ...............................................................................................................................................
    [Show full text]
  • Official Results Book Nur-Sultan 2019 World Para Powerlifting Championships Senior
    OFFICIAL RESULTS BOOK NUR-SULTAN 2019 WORLD PARA POWERLIFTING CHAMPIONSHIPS SENIOR ASTANA CONGRESS CENTER World Para Powerlifting Championships 2019 COMPETITION SCHEDULE As of 19 JUL 2019 Start Estimated Date Event Time Finish Time SAT 13 JUL 11:30 12:24 Women's Up to 41kg, Group B 12:24 13:25 Women's Up to 41kg, Group A 14:30 15:18 Men's Up to 49kg, Group C 15:18 16:06 Men's Up to 49kg, Group B 16:06 16:55 Men's Up to 49kg, Group A 17:45 18:39 Women's Up to 45kg, Group B 18:39 19:35 Women's Up to 45kg, Group A SUN 14 JUL 11:30 12:18 Men's Up to 54kg, Group B 12:18 13:05 Men's Up to 54kg, Group A 14:30 15:18 Men's Up to 59kg, Group C 15:18 16:06 Men's Up to 59kg, Group B 16:06 17:00 Men's Up to 59kg, Group A 18:00 18:48 Women's Up to 50kg, Group B 18:48 19:35 Women's Up to 50kg, Group A MON 15 JUL 11:30 12:18 Women's Up to 55kg, Group B 12:18 13:05 Women's Up to 55kg, Group A 14:30 15:30 Women's Up to 61kg, Group B 15:30 16:30 Women's Up to 61kg, Group A 17:15 18:03 Men's Up to 65kg, Group C 18:03 18:51 Men's Up to 65kg, Group B 18:51 19:45 Men's Up to 65kg, Group A TUE 16 JUL 15:00 15:54 Men's Up to 72kg, Group C 15:54 16:54 Men's Up to 72kg, Group B 16:54 17:55 Men's Up to 72kg, Group A 18:15 19:09 Men's Up to 80kg, Group D 19:09 20:03 Men's Up to 80kg, Group C 20:03 21:03 Men's Up to 80kg, Group B 21:03 22:00 Men's Up to 80kg, Group A WED 17 JUL 10:00 10:54 Women's Up to 67kg, Group B 10:54 11:55 Women's Up to 67kg, Group A 12:45 13:24 Women's Up to 73kg, Group B 13:24 14:25 Women's Up to 73kg, Group A 15:15 15:57 Women's Up to 79kg,
    [Show full text]
  • Turkey: Background and U.S. Relations
    Turkey: Background and U.S. Relations Updated November 9, 2020 Congressional Research Service https://crsreports.congress.gov R41368 SUMMARY R41368 Turkey: Background and U.S. Relations November 9, 2020 U.S.-Turkey tensions have raised questions about the future of bilateral relations and have led to congressional action against Turkey, including informal holds on major new arms sales (such as Jim Zanotti upgrades to F-16 aircraft) and efforts to impose sanctions. Nevertheless, both countries’ officials Specialist in Middle emphasize the importance of continued U.S.-Turkey cooperation and Turkey’s membership in Eastern Affairs NATO. Observers voice concerns about the largely authoritarian rule of Turkish President Recep Tayyip Erdogan. Turkey’s polarized electorate could affect Erdogan’s future leadership. His biggest challenge may be structural weaknesses in Turkey’s economy—including a sharp decline Clayton Thomas Analyst in Middle Eastern in Turkey’s currency—that have worsened since the Coronavirus Disease 2019 pandemic began. Affairs The following are key factors in the U.S.-Turkey relationship. Turkey’s strategic orientation and U.S./NATO basing. Traditionally, Turkey has relied closely on the United States and NATO for defense cooperation, European countries for trade and investment, and Russia and Iran for energy imports. A number of complicated situations in Turkey’s surrounding region— including those involving Syria, Libya, Nagorno-Karabakh (a region disputed by Armenia and Azerbaijan), and Eastern Mediterranean energy exploration—affect its relationships with the United States and other key actors, as Turkey seeks a more independent role. President Erdogan’s concerns about maintaining his parliamentary coalition with Turkish nationalists may partly explain his actions in some of the situations mentioned above.
    [Show full text]
  • Start List IRONMAN 70.3 Dubai, 2021 Search Your Name Use "Crtl F"
    Start list IRONMAN 70.3 Dubai, 2021 Search your name use "Crtl F" BIB Surname First Name AGE GROUP AWA TRICLUB Country Represented 101 Elfassi David M30-34 AWA Silver ONTRISPORTS CYP (Cyprus) 110 Dzhakishev Ablay M30-34 KAZ (Kazakhstan) 104 Fischman Ben M35-39 CYP (Cyprus) 111 Karim Iskander M30-34 KAZ (Kazakhstan) USA (United States of 109 Perez Jose M40-44 America) 102 Fischman Ido M30-34 AWA Silver ONTRISPORTS HUN (Hungary) 106 Pritasil Tomas M45-49 AWA Silver CZE (Czech Republic) 112 Kaztayez Aldiyar M40-44 KAZ (Kazakhstan) 107 Galinskiy Sandro M25-29 KAZ (Kazakhstan) 103 Beltran Jose M50-54 AWA Gold MEX (Mexico) 113 Turniyazov Nurlan M35-39 KAZ (Kazakhstan) 105 hayon roey M35-39 CYP (Cyprus) 114 Jaxybekov Adilbek M65-69 KAZ (Kazakhstan) If your club is not listed, please log into your IRONMAN Account (www.ironman.com/login) and connect your IRONMAN Athlete Profile with your club. If you are not able to find your club, please contact [email protected] Start list IRONMAN 70.3 Dubai, 2021 Search your name use "Crtl F" BIB Surname First Name AGE GROUP AWA TRICLUB Country Represented 108 Kanayev Yerzhan M35-39 MyProCoach KAZ (Kazakhstan) 115 Gorbachev Alexey M45-49 KAZ (Kazakhstan) 116 Zhaparov Yerzhan M40-44 KAZ (Kazakhstan) 117 Marescia Gary M50-54 ZAF (South Africa) 121 Marovic Mirna F45-49 AWA Gold Triathlon club Maksimir HRV (Croatia) 122 McCulloch Clare F45-49 AWA Gold TriDubai GBR (United Kingdom) 123 Cookson Sophie F30-34 AWA Silver TriDubai GBR (United Kingdom) 124 Kohler Neri Christine F45-49 CHE (Switzerland) 125 Groensedt Heidi F45-49 AWA Gold TriDubai DNK (Denmark) 126 Váczi Krisztina F35-39 HUN (Hungary) 127 arjeh lama F45-49 AWA Silver TriDubai SYR (Syrian Arab Republic) 128 Cser Beatrix F45-49 AWA Gold SOAS/Hansym Racing HUN (Hungary) 129 Betley Melika F50-54 GBR (United Kingdom) If your club is not listed, please log into your IRONMAN Account (www.ironman.com/login) and connect your IRONMAN Athlete Profile with your club.
    [Show full text]
  • The Global Fund 2014 Annual Financial Report
    31 December 2014 1 2014 Annual Financial Report The Global Fund 2014 Annual Financial Report 3 2014 Annual Financial Report Table of Contents LETTER FROM THE CHAIR AND VICE-CHAIR OF THE BOARD 5 MANAGEMENT DISCUSSION AND ANALYSIS 6 2014 Key Operational Activities 9 2014 Financial Commentary 13 Global Fund Priorities for 2015 20 CONSOLIDATED FINANCIAL STATEMENTS 23 REPORT OF THE INDEPENDENT AUDITOR 24 Consolidated Statement of Income 26 Consolidated Statement of Financial Position 27 Consolidated Statement of Cash Flows 28 Consolidated Statement of Changes in Funds 28 Notes to the Consolidated Financial Statements 29 5 2014 Annual Financial Report Letter from Chair and Vice-Chair of the Board When we took up our responsibilities as Board Leadership in 2013 we underlined the importance of the Global Fund’s various roles as a finance mechanism and actor in the field of global health, with the specific mission of fighting AIDS, tuberculosis, and malaria. We noted the breadth of our partnerships, involving governments, civil society, communities of affected people, the private sector, and technical partners. In our letter of 1 August 2013 to the Board, we indicated our conviction that the Board would “need to focus more of its attention on its fiscal strategies and practices – to ensure that resources are managed by the Fund as effectively and efficiently as possible.” We have been pleased to see the serious commitment of many players to a variety of efforts which strengthen effective financial management of Global Fund assets. Working together and in their respective roles, the Board, Committees, and Secretariat have given birth to and approved a revised Comprehensive Funding Policy.
    [Show full text]
  • List of Participants
    List of participants 68th session Economic Commission for Europe Start Date: Tuesday, April 09, 2019 End Date: Wednesday, April 10, 2019 Participants: 325 Governments (UNECE Bodies) - ECE Member States Albania H.E. Ms. Ravesa LLESHI Rue du Môle 32 1201 Geneva Ambassador Switzerland Permanent Representative Permanent Mission of the Republic of Albania to the United Nations Office and other international organizations in Geneva Mrs. Eriselda ÇOBO Blv. "Dëshmorët e Kombit", Nr.1 1001 Tirana Coordinator Albania Department for Development and Good Governance - Prime Minister's Office Mr. Fatjon DEMNERI Rue du Môle 32 1201 Genève First Secretary Switzerland Permanent Mission of the Republic of Albania to the United Nations Office and other international organizations in Geneva Mrs. Erjola MUKA Bulevardi Deshmoret e Kombit, Nr.1 1001 Tirana Director Albania Directory for Policies and Priorities for Development Prime Minister's Office Website: www.kryeministria.al Austria H.E. Mrs. Elisabeth TICHY-FISSLBERGER Avenue Giuseppe Motta 35-37 (HoD) 1202 Geneva Switzerland Ambassador Permanent Mission of Austria to the United Nations Office and specialized institutions in Geneva Ms. Charline VAN DER BEEK Avenue Giuseppe Motta 35-37 1202 Geneva Attaché Switzerland Permanent Mission of Austria to the United Nations Office and specialized institutions in Geneva 1 Thursday, April 11, 2019 68th session Economic Commission for Europe Governments (UNECE Bodies) - ECE Member States Ms. Sandra GRAF 35-37 Avenue Giuseppe Motta 1202 Geneva Advisor Switzerland Permanent Mission of Austria to the United Nations Office and specialized institutions in Geneva Azerbaijan H.E. Mr. Mahmud MAMMAD-GULIYEV (HoD) Shikhali Gurbanov str. 50 AZ1009 Baku Deputy Minister Azerbaijan Ministry of Foreign Affairs of the Republic of Azerbaijan H.E.
    [Show full text]
  • Azerbaijan Banks Association SUMMARY of the BANKING
    Azerbaijan Banks Association SUMMARY OF THE BANKING SYSTEM OF THE REPUBLIC OF AZERBAIJAN “Qafqaz” Baku 2007 Azerbaijan Banks Association: SUMMARY OF THE BANKING SYSTEM OF THE REPUBLIC OF AZERBAIJAN Baku, Publishing house “Qafqaz”, 2008, 189 pp. Compilers: Ruslan SADIRKHANOV (head of the group), Farhad ALIYEV , Namik KASUMOV , Latif KENGERLINSKIY , Yunus ABDULOB (executive secretary), Orhan KALBIYEV , Ulviyya HASAYEVA (a technical proof-reader), Soltan MAMMADOV (assistant). ISBN 9952-432-17-8 This book presents a systematized information on banking sector of Azerbaijan in the context of macroeconomic indicators of the country development. © Azerbaijan Banks Association 1 CONTENTS USED ACRONYMS AND ABBREVIATIONS.................................................................................................................... 1 INTRODUCTION.................................................................................................................................................................. 2 BACKGROUND OF THE ABA MEMBER BANKS AND THEIR MAIN DEVELOPMENT INDICATORS IN 2007.... 4 AF-BANK .............................................................................................................................................................................. 5 AMRAHBANK...................................................................................................................................................................... 8 ATABANK..........................................................................................................................................................................
    [Show full text]
  • Global Fund Observer
    Global Fund Observer NEWSLETTER Issue 231: 11 November 2013 GFO is an independent newsletter about the Global Fund. To download Word and PDF versions of this issue, click here. GFO Live >> Aidspan Website >> Contact GFO >> CONTENTS OF THIS ISSUE: Editor’s Note: (1) Several of the articles in this issue relate to the allocation methodology for the new funding model. Readers may wish to consult a new Aidspan paper, “The NFM Allocation Methodology Explained,” which is available on the Aidspan website here. (2) This has been a busy period for news about the Global Fund. In addition to the Board meeting just concluded, and the many papers prepared for that meeting, there has been news about the NFM-related decisions taken by the Strategy, Investment and Impact Committee, the Fourth Replenishment and the latest wave of funding decisions taken by the Board through electronic voting. There was not enough space to cover all of these stories in this issue of the newsletter. We invite readers to consult the “Also Available on GFO Live” section at the end of the newsletter for links to articles on these other stories. 1. NEWS: Main Decisions Made at Board Meeting This article provides a summary of the main decisions made by the Global Fund Board at its 30th meeting in Geneva on 7–8 November 2013. 2. NEWS: Revised Eligibility Policy Retains the Main Elements of the Old Policy The revised eligibility policy adopted by the Global Fund Board retains most of the main elements of the old policy. However, under the revised policy, countries that become newly ineligible will benefit from a new transition provision.
    [Show full text]
  • Diplomatic List
    United States Department of State Diplomatic List Fall 2020 Preface This publication contains the names of members of the diplomatic staff of all missions and their spouses. Members of the diplomatic staff are those mission members having diplomatic rank. These persons, with the exception of those identified by asterisks, enjoy full immunity under provisions of the Vienna Convention on Diplomatic Relations. Pertinent provisions of the Convention include the following: Article 29 The person of a diplomatic agent shall be inviolable. He shall not be liable to any form of arrest or detention. The receiving State shall treat him with due respect and shall take all appropriate steps to prevent any attack on his person, freedom, or dignity. Article 31 A diplomatic agent shall enjoy immunity from the criminal jurisdiction of the receiving State. He shall also enjoy immunity from its civil and administrative jurisdiction, except in the case of: (a) a real action relating to private immovable property situated in the territory of the receiving State, unless he holds it on behalf of the sending State for the purposes of the mission; (b) an action relating to succession in which the diplomatic agent is involved as an executor, administrator, heir or legatee as a private person and not on behalf of the sending State; (c) an action relating to any professional or commercial activity exercised by the diplomatic agent in the receiving State outside of his official functions. -- A diplomatic agent’s family members are entitled to the same immunities unless they are United States Nationals. ASTERISKS (*) IDENTIFY UNITED STATES NATIONALS.
    [Show full text]